Wall Street brokerages predict that OncoSec Medical Incorporated (NASDAQ:ONCS) will report earnings of ($0.23) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for OncoSec Medical’s earnings, with estimates ranging from ($0.24) to ($0.22). OncoSec Medical posted earnings of ($0.39) per share in the same quarter last year, which suggests a positive year over year growth rate of 41%. The firm is expected to report its next quarterly earnings report on Thursday, October 12th.

According to Zacks, analysts expect that OncoSec Medical will report full year earnings of ($1.05) per share for the current financial year, with EPS estimates ranging from ($1.14) to ($1.00). For the next fiscal year, analysts expect that the business will report earnings of ($0.97) per share, with EPS estimates ranging from ($1.02) to ($0.91). Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for OncoSec Medical.

OncoSec Medical (NASDAQ:ONCS) last issued its quarterly earnings results on Thursday, June 1st. The biotechnology company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.06.

ONCS has been the subject of several research reports. Noble Financial reissued a “buy” rating on shares of OncoSec Medical in a report on Sunday, March 19th. Maxim Group reissued a “buy” rating and set a $5.00 price target on shares of OncoSec Medical in a report on Friday, May 12th. HC Wainwright reissued a “buy” rating and set a $6.00 price target on shares of OncoSec Medical in a report on Friday, June 2nd. Dawson James reissued a “buy” rating and set a $5.00 price target on shares of OncoSec Medical in a report on Thursday, July 6th. Finally, ValuEngine cut OncoSec Medical from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $5.50.

COPYRIGHT VIOLATION WARNING: This article was first posted by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/07/11/zacks-analysts-anticipate-oncosec-medical-incorporated-oncs-will-announce-earnings-of-0-23-per-share.html.

Shares of OncoSec Medical (NASDAQ:ONCS) traded up 1.85% on Tuesday, hitting $1.10. The stock had a trading volume of 52,537 shares. OncoSec Medical has a 52 week low of $0.88 and a 52 week high of $2.08. The stock’s 50-day moving average price is $1.06 and its 200 day moving average price is $1.23. The company’s market cap is $23.28 million.

About OncoSec Medical

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.

Get a free copy of the Zacks research report on OncoSec Medical (ONCS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OncoSec Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.